http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101455055-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-08 |
| filingDate | 2011-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101455055-B1 |
| titleOfInvention | Vaccine composition based on sticholysin encapsulated into liposomes |
| abstract | The present invention relates to the field of biotechnology applied to human health. The present disclosure describes a vaccine vehicle and the toxins from eukaryotic organisms are lipidic compositions that can be administered subcutaneously or intramuscularly, Is encapsulated with multilamellar vesicles obtained by a dehydration-rehydration process with a 1: 1 molar ratio of phosphatidylcholine (DPPC): cholesterol (cho). Such a composition does not require the use of other reinforcing agents. The composition to be published is capable of modulating the CTL-specific immune response to one or more antigens co-encapsulated with toxin-containing liposomes. The vaccine progenitor of the present invention has advantages over other technologies disclosed by the prior art due to the robustness and function of immune response characteristics as well as the functionality and robustness of the CTL-specific immune response Respectively. |
| priorityDate | 2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.